Kaasim Mahmood
InvestorPartner at Advent Life Sciences
London
Writes $25K β $5M checks Β· typically $1M
Find your path to Kaasim
29 people in our graph share verified history with Kaasim β schools, employers, funds. One of them is your warm intro.
About
Kaasim Mahmood joined Advent in 2005, bringing experience in clinical medicine, finance, and mergers and acquisitions. He earned an MB BS from the Royal Free and University College Medical School in London and previously worked at Cutfield, Freeman and Co, a London corporate finance firm. At Advent he has worked on direct investments and supported the legal and financial aspects of many others.
ContactΒ· self-published, not guessed
Invests in
Biotech
Experience
- Advent Life Sciences LLPGeneral Partnercurrent2011 β presentLondon Area, United Kingdom
- Advent Venture PartnersPrincipal2005 β 2012
- Cutfield Freeman & CoAssociate2001 β 2005
Investments
Investor
Cn CreativeKandy TherapeuticsSpeciality European Pharma
Per the firm's website.
Colleagues at Advent Life Sciences
Network4
Investors connected to Kaasim in public investor directories β a warm-intro map.
Frequently asked questions
- Who is Kaasim Mahmood?
- Kaasim Mahmood joined Advent in 2005, bringing experience in clinical medicine, finance, and mergers and acquisitions. He earned an MB BS from the Royal Free and University College Medical School in London and previously worked at Cutfield, Freeman and Co, a London corporate finance firm. At Advent he has worked on direct investments and supported the legal and financial aspects of many others.
- Where does Kaasim Mahmood work?
- Kaasim Mahmood is Partner at Advent Life Sciences.
- What does Kaasim Mahmood invest in?
- Kaasim Mahmood invests in Biotech.
- What check size does Kaasim Mahmood write?
- Kaasim Mahmood typically writes checks of $25K β $5M.
- What boards does Kaasim Mahmood sit on?
- Kaasim Mahmood holds tracked board seats at F2G, Nerre Therapeutics, Orphalan, Ventus Medical.
- What companies has Kaasim Mahmood invested in?
- Investments tracked here include Cn Creative, Kandy Therapeutics, Speciality European Pharma.













